United Therapeutics: FDA accepts supplemental NDA for nebulized Tyvaso
United Therapeutics said the FDA accepted a supplemental new drug application for nebulized Tyvaso to treat idiopathic pulmonary fibrosis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.